RT  - Signa Vitae
ID  - 10.22514/SV101.062015.20
T1  - An overview of thrombolytic therapy for pulmonary embolism: a single centre experience
A1  - NIKOLINA MARIĆ
A1  - MAJA MAČKOVIĆ
A1  - NIKOLA UDILJAK
A1  - DINKO BEKIĆ
K1  - pulmonary embolism
K1  - thrombo-lytic therapy
K1  - right ventricular dysfunction
K1  - bleeding
YR  - 2015
SP  - 68
AB  - <p>Pulmonary embolism (PE) is considered to be a major cause of mortality, morbidity and hospitalization in Europe. Haemody-namic benefits of thrombolysis in patients with shock and hypotension are undeni-able, but the role of thrombolytic therapy on the outcome of haemodynamically sta-ble patients still remains controversial. This is a retrospective analysis of patients with acute PE treated with thrombolytic therapy in medical intensive care unit (ICU), University Hospital Sveti Duh, be-tween March 2014 and April 2015 . Twenty two of 75 (29%) patients with PE received thrombolytic therapy. The mean age of patients was 63 years, 45% were male and 55% female. The major symp-toms were: dyspnea (73%), chest pain (18%) and syncope (9%). 27% of patients receiving thrombolytic therapy were haemodynamically unstable and 73% were stable. All patients had an extensive clot burden on computed tomographic pul-monary angiography (CTPA). All haemo-dynamically stable patients had echocar-diographic signs of right ventricular (RV) dysfunction. Troponin I was positive in all haemodynamically unstable patients and in 50% of haemodynamically stable pa-tients. Only one (5%) haemodynamically unstable patient died but not because of PE or therapy complication. All other patients survived and recovered completely. Two patients (9%) had major non-intracranial bleeding complications, which were suc-cessfully treated with supportive therapy. </p>